NOVO NORDISK, INC. — Lobbying Disclosure | Poliscope

NOVO NORDISK, INC.

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$68.3M

Filings

503

Firms Hired

Active Period

2004–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$4,600,000	32	12
2025	$7,230,000	52	13
2024	$5,260,000	44	11
2023	$6,319,615	43	10
2022	$4,630,000	24	6
2021	$3,210,000	22	7
2020	$2,580,000	26	7
2019	$2,780,000	24	5
2018	$4,007,600	16	3
2017	$4,450,000	14	3
2016	$3,422,000	20	5
2015	$2,610,000	19	4
2014	$2,340,000	18	4
2013	$2,560,000	18	5
2012	$2,240,000	27	6
2011	$2,686,000	24	6
2010	$2,355,000	20	5
2009	$1,725,000	21	5
2008	$1,280,000	19	4
2007	$960,000	7	3
2006	$300,000	3	2
2005	$650,000	4	2
2004	$60,000	6	2

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
NOVO NORDISK, INC.	$68,255,215	93
ALSTON & BIRD LLP	—	54
NVG, LLC	—	29
PODESTA GROUP, INC.	—	30
WILLIAMS AND JENSEN, PLLC	—	29
TARPLIN, DOWNS & YOUNG, LLC	—	29
ARNOLD & PORTER KAYE SCHOLER LLP	—	15
HOLLAND & KNIGHT LLP	—	21
TODD STRATEGY GROUP	—	16
THE MADISON GROUP	—	9
DLA PIPER LLP (US)	—	18
BALLARD PARTNERS	—	7
AVOQ, LLC	—	13
CHECKMATE GOVERNMENT RELATIONS	—	8
THE NICKLES GROUP, LLC	—	8

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	421
SENATE	412
Health & Human Services, Dept of (HHS)	233
Centers For Medicare and Medicaid Services (CMS)	139
Executive Office of the President (EOP)	52
White House Office	47
Office of Management & Budget (OMB)	46
Food & Drug Administration (FDA)	43
Natl Institutes of Health (NIH)	39
Natl Economic Council (NEC)	29
Centers For Disease Control & Prevention (CDC)	28
Patent & Trademark Office (PTO)	17
Treasury, Dept of	16
U.S. Trade Representative (USTR)	14
Veterans Affairs, Dept of (VA)	11
Commerce, Dept of (DOC)	10
Labor, Dept of (DOL)	9
Homeland Security, Dept of (DHS)	8
Health Resources & Services Administration (HRSA)	7
State, Dept of (DOS)	6

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	437
Medicare/Medicaid	Medicare/Medicaid	358
Budget/Appropriations	Budget/Appropriations	283
Pharmacy	Pharmacy	172
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	145
Copyright/Patent/Trademark	Copyright/Patent/Trademark	125
Trade (domestic/foreign)	Trade (domestic/foreign)	56
Defense	Defense	40
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	30
Veterans	Veterans	19
Government Issues	Government Issues	16
Law Enforcement/Crime/Criminal Justice	Law Enforcement/Crime/Criminal Justice	15
Foreign Relations	Foreign Relations	13
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	6
Tariff (miscellaneous tariff bills)	Tariff (miscellaneous tariff bills)	6
Constitution	Constitution	3
Homeland Security	Homeland Security	3

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX.

Client expense: — · Firm income: $60,000

Matched citations: HR6509

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX.

Client expense: — · Firm income: $60,000

Matched citations: S3794

S. 150118th Congress

Affordable Prescriptions for Patients Act of 2023

2026 · third_quarter · Firm: NOVO NORDISK, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, Safe Drugs Act and Pharmaceutical Compounding.

Client expense: $2,010,000 · Firm income: —

Matched citations: S. 150

S. 150118th Congress

Affordable Prescriptions for Patients Act of 2023

2026 · third_quarter · Firm: NOVO NORDISK, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, Safe Drugs Act and Pharmaceutical Compounding.

Client expense: $2,010,000 · Firm income: —

Matched citations: S. 150

Show 21 more cited filings

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · third_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Monitored issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 1

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · third_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 1492

H.R. 2715119th Congress

Destruction of Hazardous Imports Act

2026 · third_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to compounding and counterfeit drugs. H.R. 2715, Destruction of Hazardous Imports Act.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 2715

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2026 · third_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Client expense: — · Firm income: $80,000

Matched citations: H.R. 4231

S. 1973119th Congress

Treat and Reduce Obesity Act of 2025

2026 · third_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Client expense: — · Firm income: $80,000

Matched citations: S. 1973

H.R. 1117th Congress

For the People Act of 2021

2026 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794).

Client expense: — · Firm income: $60,000

Matched citations: HR6509

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794).

Client expense: — · Firm income: $60,000

Matched citations: S3794

S. 150118th Congress

Affordable Prescriptions for Patients Act of 2023

2026 · second_quarter · Firm: NOVO NORDISK, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding.

Client expense: $1,300,000 · Firm income: —

Matched citations: S. 150

S. 150118th Congress

Affordable Prescriptions for Patients Act of 2023

2026 · second_quarter · Firm: NOVO NORDISK, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding.

Client expense: $1,300,000 · Firm income: —

Matched citations: S. 150

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · second_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Monitored issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 1

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · second_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 1492

H.R. 2715119th Congress

Destruction of Hazardous Imports Act

2026 · second_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to compounding and counterfeit drugs. H.R. 2715, Destruction of Hazardous Imports Act.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 2715

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2026 · second_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Client expense: — · Firm income: $70,000

Matched citations: H.R. 4231

S. 1973119th Congress

Treat and Reduce Obesity Act of 2025

2026 · second_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Client expense: — · Firm income: $70,000

Matched citations: S. 1973

S. 150118th Congress

Affordable Prescriptions for Patients Act of 2023

2026 · first_quarter · Firm: NOVO NORDISK, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding

Client expense: $1,290,000 · Firm income: —

Matched citations: S. 150

S. 150118th Congress

Affordable Prescriptions for Patients Act of 2023

2026 · first_quarter · Firm: NOVO NORDISK, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding

Client expense: $1,290,000 · Firm income: —

Matched citations: S. 150

H.R. 1117th Congress

For the People Act of 2021

2026 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · first_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Monitored issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 1

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · first_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 1492

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2026 · first_quarter · Firm: ARNOLD & PORTER KAYE SCHOLER LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Client expense: — · Firm income: $80,000

Matched citations: H.R. 4231

Source: Senate LDA